This is the authors' abstract. We don't add key points for this paper.
Pituitary neuroendocrine tumors (PitNETs) pose diagnostic and therapeutic challenges due to their heterogeneity and complex endocrine-metabolic interactions. Artificial intelligence (AI) enhances PitNET management through improved classification, outcome prediction, and personalized treatment. However, current AI models face limitations, including small, single-center datasets and insufficient integration of multi-omics or autoimmune-associated biomarkers. Future advancements require multicenter standardized databases, explainable AI frameworks, and multimodal data fusion. By decoding endocrine-metabolic dysregulation and its link to tumor behavior, AI-driven precision medicine can optimize PitNET care. This review highlights AI's potential in PitNETs while addressing key challenges and future directions for clinical translation.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: